A new mechanism for Cannabidiol in regulating the one-carbon cycle and methionine levels in Dictyostelium and in mammalian epilepsy models by Perry, Christopher J. et al.
A new mechanism for Cannabidiol in 
regulating the one-carbon cycle and 
methionine levels in Dictyostelium and in 
mammalian epilepsy models 
Article 
Published Version 
Creative Commons: Attribution 4.0 (CC-BY) 
Open access 
Perry, C. J., Finch, P., Muller-Taubenberger, A., Leung, K.-Y., 
Warren, E. C., Damstra-Oddy, J., Sharma, D., Patra, P. H., 
Glyn, S., Boberska, J., Stewart, B., Baldwin, A., Piscitelli, F., 
Harvey, R. J., Harwood, A., Thompson, C., Claus, S. P., 
Greene, N. D. E., McNeish, A. J., Williams, C. M., Whalley, B. 
J. and Williams, R. S. B. (2020) A new mechanism for 
Cannabidiol in regulating the one-carbon cycle and methionine 
levels in Dictyostelium and in mammalian epilepsy models. 
British Journal of Pharmacology, 177 (4). pp. 912-928. ISSN 
0007-1188 doi: https://doi.org/10.1111/bph.14892 Available at 
http://centaur.reading.ac.uk/86405/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work.  See Guidance on citing .
To link to this article DOI: http://dx.doi.org/10.1111/bph.14892 
Publisher: Wiley 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
R E S E A R CH P A P E R
A new mechanism for cannabidiol in regulating the one-carbon
cycle and methionine levels in Dictyostelium and in mammalian
epilepsy models
Christopher J. Perry1 | Paul Finch1 | Annette Müller-Taubenberger2 |
Kit-Yi Leung3 | Eleanor C. Warren1 | Joseph Damstra-Oddy1 | Devdutt Sharma1 |
Pabitra H. Patra4 | Sarah Glyn4 | Joanna Boberska4 | Balint Stewart5 |
Amy Baldwin6 | Fabiana Piscitelli7 | Robert J. Harvey8,9 | Adrian Harwood6 |
Christopher Thompson5 | Sandrine P. Claus4 | Nicholas D.E. Greene4 |
Alister J. McNeish4 | Claire M. Williams4 | Benjamin J. Whalley4 |
Robin S.B. Williams1
1Centre for Biomedical Sciences, Department
of Biological Sciences, Royal Holloway
University of London, Egham, UK
2Department of Cell Biology, Biomedical
Center, LMU Munich, Planegg, Germany
3Development Biology and Cancer Program,
UCL Great Ormond Street Institute of Child
Health, London, UK
4The School of Chemistry, Food Biosciences and
Pharmacy, University of Reading, Reading, UK
5Faculty of Life Sciences, Manchester
University, Manchester, UK
6Neuroscience and Mental Health Research
Institute, Cardiff University, Cardiff, UK
7Institute of Biomolecular Chemistry, Consiglio
Nazionale delle Ricerche, Rome, Italy
8School of Health and Sport Sciences,
University of the Sunshine Coast, Sippy
Downs, QLD, Australia
9Sunshine Coast Health Institute, University of
the Sunshine Coast, Birtinya, QLD, Australia
Correspondence
Robin S. B. Williams, Centre for Biomedical
Sciences, Department of Biological Sciences,
Royal Holloway University of London, Egham,
Surrey TW20 0EX, UK.
Email: robin.williams@rhul.ac.uk
Background and Purpose: Epidiolex™, a form of highly purified cannabidiol (CBD)
derived from Cannabis plants, has demonstrated seizure control activity in patients
with Dravet syndrome, without a fully elucidated mechanism of action. We have
employed an unbiased approach to investigate this mechanism at a cellular level.
Experimental Approach: We use a tractable biomedical model organism,
Dictyostelium, to identify a protein controlling the effect of CBD and characterize this
mechanism. We then translate these results to a Dravet syndrome mouse model and
an acute in vitro seizure model.
Key Results: CBD activity is partially dependent upon the mitochondrial glycine
cleavage system component, GcvH1 in Dictyostelium, orthologous to the human
glycine cleavage system component H protein, which is functionally linked to folate
one-carbon metabolism (FOCM). Analysis of FOCM components identified a
mechanism for CBD in directly inhibiting methionine synthesis. Analysis of brain
tissue from a Dravet syndrome mouse model also showed drastically altered levels of
one-carbon components including methionine, and an in vitro rat seizure model
showed an elevated level of methionine that is attenuated following CBD treatment.
Conclusions and Implications: Our results suggest a novel mechanism for CBD in the
regulating methionine levels and identify altered one-carbon metabolism in Dravet
syndrome and seizure activity.
Abbreviations: 5mTHF, 50methyl THF; bsR, blasticidin S deaminase; CBD, cannabidiol;
FOCM, folate one-carbon metabolism; GCS, glycine cleavage system; GCSH, human glycine
cleavage system component H; GCVH1, Dictyostelium glycine cleavage system component
H1; THF, tetrahydrofolate.
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1 | INTRODUCTION
The use of Cannabis extracts as a medicinal treatment has been
recorded for nearly 2,000 years (BRAND & ZHAO, 2017), covering a
range of disorders including pain management, multiple sclerosis, and
epilepsy (Devinsky et al., 2014). Of the ~100 cannabinoids found
within, or derived from, Cannabis species, cannabidiol (CBD) is among
the most abundant of the non-psychoactive cannabinoids and has
received considerable interest as a therapeutic treatment (Jones et al.,
2010; Jones et al., 2012). CBD has been shown to provide
antiepileptiform and anti-seizure properties within numerous in vitro
and in vivo mammalian epilepsy models (Jones et al., 2012; Klein et
al., 2017). CBD is also used as a lead cannabinoid-based treatment for
severe epilepsies such as Dravet syndrome (Devinsky et al., 2017) and
Lennox–Gastaut syndrome (Devinsky et al., 2018; Thiele et al., 2018).
A range of targets for CBD in seizure control have also been identi-
fied, including glycine receptors (Xiong et al., 2012), GPR55 (Kaplan,
Stella, Catterall, & Westenbroek, 2017), NMDA receptors (Rodriguez-
munoz, Onetti, Cortes-Montero, Garzon, & Sanchez-Blazquez, 2018),
transient receptor potential of vanilloid type-1 channels (Vilela et al.,
2017) and voltage-dependent anion selective channels (Rimmerman
et al., 2013).
The cell and molecular basis of epilepsy and seizures is
well-accepted to be related to electrical signalling and ion channel
activity; however, a range of models have suggested that deregula-
tion of several key amino acids is also involved in, or associated
with, seizures and epilepsy (Bejarano & Rodriguez-navarro, 2015;
Gupta et al., 2004). For example, numerous studies have proposed
altered mitochondrial function in epilepsy pathology (Doccini et al.,
2015; Kumar et al., 2016; Panneman, Smeitink, & Rodenburg, 2018;
Pearson-smith, Liang, Rowley, Day, & Patel, 2017). Mitochondria
contain the glycine cleavage system (GCS) that is responsible for
regulation of glycine levels (Kikuchi & Hiraga, 1982) subsequently
controlling numerous functions including protein synthesis and
neurotransmission (Kolker, 2018). The GCS also plays a role in
providing glycine-derived one-carbon units into the folate one-
carbon metabolism (FOCM), leading through folate-containing inter-
mediates, to production of methionine from homocysteine (Ducker
& Rabinowitz, 2017). Isotope labelling has directly demonstrated 1C
donation from glycine to FOCM in humans and mice in vivo
(Lamers et al., 2009; Leung et al., 2017). Methionine fulfils a funda-
mentally important role in protein synthesis and as a precursor to S-
adenosyl methionine (SAM) that is responsible for the transfer of a
methyl group to a number of acceptor molecules including
neurotransmitters and DNA methyltransferases (Moore, Le, & Fan,
2013). SAM is further hydrolysed to form adenosine and
homocysteine which can again be converted into methionine or
instead into cysteine. These various metabolites and amino acids
have been described as “primordial” metabolites (Boison, 2016),
suggested to provide the original components for the beginning of
life, and are thus highly conserved across many species. In addition,
many of these components are regulated by mitochondrial function
and relate to energy production, where both have been proposed as
mechanistic targets for cannabinoids (Bénard et al., 2012).
Understanding the molecular mechanisms of newly developed
medicines provides an important aspect of validation, where simple
biomedical model systems such as the social amoeba Dictyostelium
discoideum have proved effective (Cunliffe et al., 2015; Warren,
What is already known
• CBD, a key constituent of Epidiolex™, is effective in the
treatment of specific drug-resistant epilepsies.
• A full understanding of mechanisms for CBD-dependent
s eizure control remains to be established.
What does this study add
• We identified a molecular mechanisms of CBD in regulat-
ing the one-carbon cycle components including
methionine.
• We show one-carbon cycle components are deregulated
in a Dravet model and during seizure-like activity.
What is the clinical significance
• Our data will increase clinical focus on one-carbon
metabolism in epilepsy and other CBD-treatable
disorders.
• Clinical studies relating to Dravet syndrome, in particular,
will benefit from monitoring one-carbon signalling.
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Walker, & Williams, 2018). D. discoideum is a eukaryote more
evolutionarily related to animals than to plants and bacteria
that possesses a range of highly conserved signalling pathways
and proteins that have been linked to human diseases
(Müller-taubenberger, Kortholt, & Eichinger, 2013). It exists in both
a single cell stage, where cells divide by binary division, and a
multicellular stage induced by starvation leading to the formation of
small (~1 mm tall) fruiting bodies. Using D. discoideum, insertional
mutant libraries have been employed to identify genes controlling
the effect of a natural product or medicinal treatment (Cocorocchio
et al., 2018; Waheed et al., 2014), including treatments for epilepsy
(Chang et al., 2012; Warren et al., 2018) and bipolar disorder
(Kelly, Sharma, Wilkinson, & Williams, 2018; Williams, Cheng,
Mudge, & Harwood, 2002). In many of these studies, discoveries
based in D. discoideum have been subsequently validated in
mammalian models (Chang et al., 2013; Chang et al., 2015; Chang,
Walker, & Williams, 2014; Waheed et al., 2014). Thus, employing
D. discoideum to investigate the cellular mechanisms of CBD may
provide a suitable, innovative approach to identify therapeutic
mechanisms of this important cannabinoid.
In the initial phase of this study, we used D. discoideum to better
understand the molecular mechanism of CBD. We show that CBD
affects D. discoideum cell proliferation and by performing an unbiased
genome wide screen, we identify a role for the mitochondrial GCS
component, GCVH1, homologous to the human protein GSCH in this
effect. Analysis of glycine, one-carbon cycle intermediates
(methionine and cysteine), and folates confirmed a role for GCVH1 in
regulating these components through attenuating activity of the GCS
and suggested a novel molecular mechanism of CBD through
inhibition of methionine synthase activity. We then examined the
regulation of one-carbon-related amino acids in the brain of a mouse
model of Dravet syndrome (Scn1A+/−), a CBD responsive condition in
humans (Thiele et al., 2018), and identified altered levels of glycine,
methionine, and cysteine, implicating dysregulation of one-carbon
metabolism in this disease. Moreover, methionine levels were altered
in this model following chronic CBD treatment. We finally
investigated this effect using an in vitro mammalian model of seizure
activity, where methionine levels were shown to rapidly increase
during seizure activity and this increase was corrected by CBD
treatment.
2 | METHODS
2.1 | D. discoideum growth assay
D. discoideum cell lines grown in HL5 medium on a 10-cm dish
were plated onto a 24-well plate at 5 × 103 cells per well in
495 μl of media (HL5, Formedia, UK). For each well, 5 μl of CBD
from 100-mM stock in DMSO was added to achieve final
concentrations ranging from 0- to 20-μM CBD (DMSO made up
1% of final volume). Cells were maintained at 22C, counted after
72 hr (lag phase), and then every 24 hr. These data are presented
as normalized (fold change from control [untreated, Day 7]) to
correct for variation between independent experiments. Each
concentration was analysed using at least six independent
experiments, where rate of exponential cell growth (Days 4 to 6) at
each concentration was used to create secondary plots
(concentration–response curves), providing IC50 values for each cell
type (wild type, mutants, and rescue lines), determined using
non-linear regression analysis.
2.2 | D. discoideum development assay
Wild-type D. discoideum cells in the exponential phase of growth were
washed in KK2 buffer (16.2-mM KH2PO4, 4-mM K2HPO4) and
1 × 107 cells placed onto a nitrocellulose filter (Millipore, Cork).
Absorbent pads (Millipore, Cork) were placed in 2-ml culture dishes
and soaked with 0.5-ml KK2 buffer containing CBD from 100-mM
stock in DMSO to achieve a final concentration of 20 μM (DMSO
made up 1% of final volume). Nitrocellulose filters and cells were
placed upon absorbent pads and maintained in a humid environment
at 22C for 24 hr. Fruiting body morphology was recorded using a
dissection microscope and camera.
2.3 | Restriction enzyme-mediated integration
screen
A mutant library containing approximately 5,000 insertional
mutants was created by restriction enzyme-mediated integration.
Library cells taken from the exponential growth phase were
screened for resistance to 9.47-μM CBD (80% inhibitory concen-
tration) taken from 100-mM stock in DMSO. Cells were maintained
at 22C and screened over a 3-week period, with the media rep-
laced every 2 days. Resistant mutants were isolated, and isogenic
strains created. Location of the blasticidin S deaminase (bsR) inser-
tion was identified using whole-genome next-generation sequenc-
ing (NGS).
2.4 | NGS analysis
Five hundred-nanogram DNA was fragmented on the Covaris S2 to
a target size of 300 bp (intensity: 4, duty cycle: 10%, cycles-per-
burst: 200, time: 80 s). A library was then prepared using the NEB
DNA Ultra II kit (New England Biolabs, E7645), with bead selection
for 300- to 400-bp fragments and five cycles of PCR. Sequencing
was performed by UCL Genomics on an Illumina NextSeq 500,
using a 150-bp paired-end protocol. NGS assemblies were per-
formed using Sequencher software (RRID:SCR_001528), using Vel-
vet (Zerbino & Birney, 2008) for de novo assembly, or GSNAP
(RRID:SCR_005483) for bsR-cassette-guided assembly, to reveal the
sites of bsR-cassette insertions in the D. discoideum genome using
BLAST searches (RRID:SCR_001653).
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2.5 | Creation of gcvH1− cell line and
overexpression cell lines
In order to recapitulate the resistance seen in the insertional gcvH1−
mutant, a gcvH1− cell line was created via homologous recombination.
Primers to both the 50 and 30 region of gcvH1 were used to amplify
PCR products for both regions (Figure S1). A 281-bp fragment was
amplified from the 50 region, while a 343-bp fragment was amplified
of the 30 region (Figure S1). Both fragments were ligated into the
pLPBLP plasmid flanking the bsR gene with their reading frames in
opposite orientation to bsR. A knockout cassette consisting of bsR
and the flanking gcvH1 fragments was created by a SpeI/KpnI
restriction digest. Wild-type cells were transformed with the digested
plasmid by electroporation. Transformants were selected by growing
in liquid medium containing 10 μgml−1 blasticidin and screened for
homologous recombinants. Primers were designed that would
produce diagnostic knockout fragments unique to the homologously
integrated transformants, as well as the necessary controls (Figure S1).
To create a gcvH1 overexpression plasmid (Figure S1), the gcvH1
cDNA was cloned into an extra-chromosomal vector (Fischer et al.,
2004), enabling expression of the 42-kDa fluorescently labelled
protein (Figure S2). The PCR product was digested with EcoRI and
BamHI and then ligated into the extra-chromosomal plasmid pDXA-
389-2 and sequenced to confirm that no mutations were introduced.
The resulting plasmid was transformed into gcvH1− cells and selected
using geneticin (10 mgml−1) to create an overexpression cell line. A
cDNA encoding the Homo sapiens orthologue human glycine cleavage
system component H (GCSH) was codon optimized for D. discoideum
and amplified using primers 11 + 12. This was also inserted into
pDXA-389-2 and a further overexpression cell line was created that
overexpresses the human GCSH cDNA. In both cases, the
recombinant proteins were tagged with RFP at the C-terminus.
2.6 | Analysis of D. discoideum gcvH1 and
H. sapiens GCSH expression by RT-PCR
Total RNA was extracted from cell lines using an RNeasy mini-kit
(Qiagen). cDNA was synthesized from total RNA treated with DNase
(Life Technologies) using a first-strand cDNA synthesis kit (Thermo
Scientific). Gene expression was confirmed via RT-PCR using the
primers 13 + 14 for the D. discoideum gene and primers 15 + 16 for
the H. sapiens gene. A control was used based upon the constitutive
expression of the Ig7 housekeeping gene using primers 17 + 18.
2.7 | Western blot analysis to confirm the
presence of RFP fusion proteins in the overexpression
cell lines
Cell lysates from cell lines were separated by gel electrophoresis,
transferred to nitrocellulose membranes (Merck Millipore,
IPFL00010), and analysed by Western blotting. A mouse anti-RFP
primary antibody (Chromotek, 6G6 anti-RFP, 1:1,000) and a goat
anti-mouse secondary antibody (Li-Cor goat anti-mouse IRDye®,
1:1,000) were used to confirm the presence of RFP. A conjugated
anti-streptavidin antibody (Invitrogen, Streptavidin Alexa Fluor 680
conjugate) was used as a loading control. Blots were analysed using
Odyssey software.
2.8 | Fluorescence and live-cell microscopy
The immuno-related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology (Alexander et al.,
2018). For immunolabelling, gcvH1− cells, expressing either D. dis-
coideum gcvH1-RFP or H. sapiens GCSH-RFP, were plated on round
12-mm glass coverslips and after 20 min were fixed with 15% picric
acid/2% paraformaldehyde in 10-mM PIPES, pH 6.0, for 20 min and
postfixed with 70% ethanol for 10 min. Cells were then washed three
times in PBS, once with 10-mM PIPES and twice with PBS/1%
glycine, and incubated in blocking buffer (PBS plus 2% BSA) for 1 hr
at room temperature (RT). After blocking, the cells were washed three
times with PBS and incubated with primary antibodies for 2 hr at RT,
followed by the incubation with secondary antibodies and DAPI, to
stain DNA, for 1 hr at RT. After immunostaining, samples were
washed three times in PBS and embedded using Dako mounting
medium (Agilent Technologies). For visualization of filamentous actin,
cells were stained with Atto 488-phalloidin (Sigma Aldrich). In order to
visualize mitochondrial porin, cells were stained with mouse
monoclonal anti-porin antibodies (70-100-1; Troll et al., 1993), and
Alexa 488-conjugated goat anti-mouse IgG. DNA was visualized by
staining with DAPI. For live-cell microscopy, cells were seeded in
μ-dishes (Ibidi, Germany) or open chambers as described previously
(Fischer, Haase, Simmeth, Gerisch, & Muller-Taubenberger, 2004).
Confocal microscopy was performed at the Bioimaging core
facility of the Biomedical Center (LMU Munich) using an inverted
Leica TCS SP8 equipped with lasers for 405-, 488-, 552-, and 638-nm
excitation. Images were acquired with an HC PL APO 63×/1.40 oil
PH3 objective. Recording was sequentially to avoid bleed through.
Atto-488 and Alexa-488 and RFP were recorded with the hybrid
photo detectors and DAPI with the conventional photomultiplier
tube.
2.9 | Amino acid analysis by GC–MS
GC–MS analysis of amino acid levels within either cell lysate or brain
tissue was adapted from an earlier study (Svagera, Hanzlikova, Simek,
& Husek, 2012), where 40 μl of sample (cell lysate or plasma) was
spiked with 10 μl of DL-4-chlorophenylalanine (internal standard)
followed by 10 μl of the reducing agent Tris(3-hydroxypropyl)phos-
phine (0.5% w/v in water). Samples were gently mixed and left to
stand for 1 min before adding 40-μl trichloroacetic acid (0.6 M in
water), vortexed twice, and samples centrifuged at 3,000 g for 10 min.
Using 80 μl of supernatant, in a clean glass culture tube, 40 μl of a 3:1
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1-propanol:pyridine mixture was added, followed by 130 μl of a
reactive mixture containing a 10:3:1 mix of 2,2,4-trimethylpentane,
butyl acetate, and propyl chloroformate. Samples were vortexed for
30 s and centrifuged at 3,000 g for 10 s, and the upper organic phase
removed and used in GC–MS analysis. GC–MS was carried out on an
HP5890 Series II chromatograph interfaced to an HP5972 MSD mass
spectrometer; 2-μl samples were injected in splitless mode (injector
temp 240C, purge delay 1.0 min) on a J&W DB5 column or Abel AB-
5MS (30 m × 0.25 mm dia × 0.25 μ film) using helium as the carrier
gas at constant flow of 30 cms−1. The column oven was programmed
from 90C (2 min) to 300C at 7.5Cmin−1, the GC–MS interface
temperature was 300C. Retention times and mass spectra of deriva-
tives of amino acids were determined in TIC mode and confirmed to
be in agreement with library and literature data. Quantitative analysis
was carried out in SIM mode using 4-chlorophenylalanine as internal
standard. Chromatograms were integrated using MZmine (RRID:SCR_
012040) or manually using Agilent MSD Chemstation to yield peak
areas of amino acid derivatives relative to that from the internal stan-
dard, and peak areas were processed using Prism software (RRID:
SCR_005375). To ensure unbiased analysis, samples were blinded and
randomized prior to quantification. Samples size was estimated using
data from a similar technique, where calculations with an observed
effect of ≥20% suggested group size should be up to nine to observe
an effect.
2.10 | Treatment of D. discoideum with CBD for
folate and amino acid (GC–MS and NMR) analysis
Cells (5 × 106 cells) in the exponential phase of growth were plated
onto a 10-cm tissue culture dish in 10 ml of HL5 medium. Cells were
allowed to adhere for 30 min, and then the medium was replaced con-
taining 1.89-μM CBD from 100-mM stock in DMSO. Plates were
maintained at 22C for 12 hr. Following the 12-hr incubation, cells
were washed three times with KK2 buffer (16.2-mM KH2PO4, 4-mM
K2HPO4), pelleted, and stored at −80C. Prior to GC–MS analysis,
200 μl of sterile KK2 buffer with protease inhibitors was added to
samples, which were briefly vortexed and subjected to five freeze
thaw cycles from −80C to 30C. Samples were centrifuged at
5,000 g for 5 min and the cell lysate collected. The cell lysate was
further centrifuged at 21,000 g for 10 min and the lysate collected for
GC–MS analysis. To ensure unbiased analysis, samples were blinded
and randomized prior to quantification.
2.11 | Quantification of folate-mediated one-
carbon metabolism intermediates by MS
Analysis of multiple folates was performed by UPLC–MS/MS as
described previously (Leung et al., 2017; Pai et al., 2015). Buffer con-
taining 20-mM ammonia acetate, 0.1% ascorbic acid, 0.1% citric acid,
and 100-mM DTT at pH 7 was added to cell pellets. Cell suspensions
were sonicated for 10 s using a hand-held sonicator at 40% amplitude
on ice. Protein was removed by precipitation with addition of two
volumes of acetonitrile, mixing for 2 min and centrifugation for
15 min at 12,000 g and 4C. Supernatants were transferred to fresh
tubes, lyophilized, and stored at −80C prior to analysis.
Lyophilized blinded samples were resuspended in 30-μl water
(Milli-Q) and centrifuged for 5 min at 12,000 g at 4C.
Supernatants were transferred to glass sample vials for UPLC–
MS/MS analysis. Metabolites were resolved by reversed-phase
chromatography using Acquity UPLC BEH C18 column
(50 mm × 2.1 mm; 1.7-μm bead size, Waters Corporation, UK).
Solvents for UPLC were buffer A, 5% methanol, 95% Milli-Q water,
and 5-mM dimethylhexylamine at pH 8.0; buffer B, 100% methanol.
The column was equilibrated with 95% buffer A: 5% buffer B. The
sample injection volume was 25 μl. The UPLC protocol consisted of
95% buffer A: 5% buffer B for 1 min, followed by a gradient of
5–60% buffer B over 9 min and then 100% buffer B for 6 min
before re-equilibration for 4 min. The metabolites were eluted at a
flow rate of 500 nlmin−1. The UPLC was coupled to a XEVO-TQS
mass spectrometer (Waters Corporation, UK) operating in
negative-ion mode using the following settings: capillary 2.5 kV,
source temperature 150C, desolvation temperature 600C, cone
gas flow rate 150 Lhr−1, and desolvation gas flow rate
1,200 Lhr−1. Folates were measured by multiple reaction
monitoring with optimized cone voltage and collision energy for
precursor and product ions (as described in Leung et al., 2013).
2.12 | LC–MS-IT-TOF analysis of cellular CBD
levels in D. discoideum
Cell pellets, blinded and randomized prior to quantification, were
homogenized in acetone and sonicated in an ultrasonic bath for 8 min.
An internal standard for CBD quantification by isotope dilution
(d4-CBD 10 pmol) was added to the homogenate and extracted four
times with acetone. The lipid-containing solution was dried down,
weighed, and pre-purified by open bed chromatography on silica gel.
Fractions were obtained by eluting the column with 99:1, 90:10, and
50:50 (v/v) chloroform/methanol. The 99:1 fraction was used for
CBD quantification by LC–MS-IT-TOF analysis as described
previously (Piscitelli, Pagano, Lauritano, Izzo, & Di Marzo, 2017).
2.13 | Amino acid analysis by NMR
Intracellular metabolites were extracted as previously described
(Viant, 2007). Briefly, a two-phase extract was generated using a
mixture of methanol, chloroform, and water in the volume ratio of
4:4:2.85. The aqueous phase containing water-soluble low molecular
weight endogenous metabolites was transferred to microtubes, and
solvents were removed using a vacuum concentrator Eppendorf AG
(Eppendorf, Hamburg, Germany), 8 hr at 60C. Samples were then
reconstituted in 70 μl of NMR phosphate buffer (pH 7.4) 0.2 M (80%
of D2O, 20% of H2O, 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid;
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Sigma-Aldrich) 1 mM, serving as NMR reference, vortexed for 10 s,
and centrifuged at 12 000 g at 4C for 10 min; 60 μl of resulting
supernatant was pipetted into a 1.7-mm capillary tube (Bruker, UK)
for NMR analysis.
NMR analysis was carried out using a Bruker AV700 NMR
instrument equipped with a 5-mm inverse cryoprobe. A standard
one-dimensional nuclear Overhauser effect spectroscopy experiment
was performed on each sample, using a standard preset pulse
sequence (noesypr1d, 90 pulse length at 9.25 μs, total acquisition
time of 2 s, and water pre-saturation during relaxation delay of 5 s).
All samples were analysed at 297 K and free induction decay was
acquired on 19,607 data points (spectral width 9,803.9 Hz) using 512
scans (eight dummy scans). Free induction decay was then zero filled
to 64 k points, and line broadening of 0.6 Hz was applied prior to fast
Fourier transform. Phase and baseline corrections were performed
manually using MestreNova software (version 10.0 m MestreLab
Research). NMR spectra were referenced to 3-(trimethylsilyl)
propionic-2,2,3,3-d4 acid peak at 0 ppm. All samples were blinded
prior to analysis.
2.14 | Amino acid analysis of brain samples of a
heterozygous Scn1a mouse model treated with CBD
129S-Scn1atm1Kea/Mmjax heterozygote (+/−) male mice (Jackson
Laboratory, USA), maintained in the Bioresource Unit, University of
Reading, were crossed with female C57BL/6 mice (Charles River, UK)
to obtain hybrid Scn1a heterozygote (+/−) and wild-type animals used
in this study. This strain of Scn1a+/− mice show the characteristics of
Dravet syndrome, a severe form of childhood epilepsy (Miller,
Hawkins, McCollom, & Kearney, 2014). Scn1a+/− (epileptic) animals
were randomly assigned to either vehicle (ethanol: kolliphor®: 0.9%
saline = 2:1:17; n = 10) or CBD (100 mgkg−1 twice daily subcutane-
ous injection, n = 10; GW Pharmaceuticals batch number 070214) for
6 weeks from postnatal Day 8 onwards. Likewise, a wild-type group
was taken as healthy control (n = 9) and treated with vehicle for
6 weeks. All the animals were group housed and maintained in a
12 hr:12 hr dark:light cycle at an RT of 21C and humidity of
50 ± 10%, with ad libitum access to food and water. This experiment
was conducted in the dark cycle (dim red light 8:00–20:00), and
injections were made at circa 8 a.m. and circa 8 p.m. by both male and
female experimenters. The dose of CBD used here was selected to
compare with the effective clinical dose used in humans to treat
Dravet syndrome and epilepsy in other rodent models (Patra et al.,
2019) estimated using a method as described earlier (Nair & Jacob,
2016). At the end of the treatment period, all animals were humanely
killed by cervical dislocation for collection of blood (heparinized tube;
Fisher Scientific, UK) and brain (flash frozen in liquid nitrogen). Tissue
was stored at −80C until used in amino acid analyses. The experi-
ments were conducted following UK Home Office regulations
(Animals [Scientific Procedures] Act, 1986) under licence 70/8397
“Mouse Model of Dravet Syndrome” and was approved by the Animal
Welfare and Ethics Review Board at the University of Reading. We
used previous data from a similar technique and standard sample size
calculations to estimate group size to observe an effect ≥20%,
suggesting a group size should be up to nine animals to observe an
effect. To ensure unbiased analysis, samples were blinded and ran-
domized prior to quantification. Unfortunately, we could not
determine the effect of CBD on one-carbon cycle amino acids in
healthy animals as our previous preliminary data did not warrant
inclusion of this group in a chronic dosing study as CBD is well
tolerated in healthy rodents. Animal studies are reported in
compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill,
Emerson, & Altman, 2010) and with the recommendations made by
the British Journal of Pharmacology.
2.15 | Acute seizure model of rat primary
hippocampal neurons treated with pentylenetetrazol
and CBD
Pregnant female Sprague-Drawley rats (4–5 months old) at 18 days of
gestation were culled by concussion. The embryos were removed and
5 × 105 cells were extracted from the embryo hippocampi, seeded
onto a six-well plate and matured for 21 days in modified neurobasal
medium (Thermo Fisher Scientific, UK) with B27 supplement
(1 ml/50 ml). Intervention groups were treated with CBD from
100-mM stock in DMSO to a final concentration of 1.89 μM and incu-
bated at 37C and 5% CO2 with sample provided for analysis random-
ized and blinded. After 1 hr of incubation, both intervention and
untreated cells were treated with pentylenetetrazol (PTZ) from 1-M
stock to a final concentration of 5 mM and placed at 37C and 5%
CO2 for 20-min cells. Media was aspirated and the cells were washed
three times with ice cold PBS. Cells were lysed for 10 min using
200-μl RIPA buffer containing protease inhibitors and then collected
using a cell scraper. Samples were immediately frozen at −80C and
used in subsequent GC–MS and protein analyses.
2.16 | Data and analysis
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and
analysis in pharmacology (Curtis et al., 2018). The distribution of all
experimental data was tested for using the Anderson–Darling test for
normality. All data that showed a Gaussian distribution were analysed
using parametric tests. No outliers were excluded from analysis.
Normally distributed data from two groups were statistically analysed
using a Student's t-test. The one-way ANOVA statistical test was used
to test for significance between the means of three or more
independent groups of normally distributed data. In conjunction with
the one-way ANOVA, Tukey multiple comparison tests were
performed to test for significance between all possible pairs of means.
All experimental data involving two independent variables were
analysed using a two-way ANOVA. The two-way ANOVA was used
to test for an interaction between these independent variables and
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the dependent variable. In conjunction with the two-way ANOVA, a
Bonferroni multiple comparison test was performed to test for
significance between all possible pairs of means. Post hoc analysis in
ANOVA tests was only performed if the F-test value of the ANOVA
reached significance (P < .05). N values are defined as a sample
derived from an individual animal or experiment, that is, technical
replicates were not considered as an n value. Only data with n ≥ 5
were statistically analysed. Data were considered statistically
significant if P < .05. Data provided in the results are not paired, and
thus the number in each group does not need to be identical
(providing each set of data was sufficiently powered). We have thus
always performed a minimum of six experiments and that each group
was statistically powered to see the effect size observed.
2.17 | Materials
CBD was provided by GW Research Ltd.
2.18 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2017/18
(Alexander et al., 2017).
3 | RESULTS
3.1 | Investigating cellular mechanisms of CBD in
the model system D. discoideum
To investigate a molecular mechanism of CBD, independent of
previously described targets and effects, we initially employed the
tractable model D. discoideum. Treatment with CBD at concentrations
from 0 to 20 μM caused a concentration-dependent inhibition of
unicellular growth, providing a readout for mechanistic studies
(Figure 1a). Growth inhibition had an IC50 of 1.9 μM (95% CI
[1.6–2.2 μM]; Figure 1b), where growth was significantly reduced at
0.5 μM (P < .05) and blocked at 20 μM CBD. This concentration is
close to steady-state plasma levels shown in clinical studies (Devinsky
et al., 2017; Devinsky et al., 2018), rather than high concentrations
reported in some investigations (Bih et al., 2015). These data suggest
the presence of CBD-sensitive processes in D. discoideum, with
regulation of a potential target at similar concentrations shown to
block seizure activity in mammalian models (Jones et al., 2012; Kaplan
et al., 2017; Klein et al., 2017).
We continued by analysing the effect of CBD on D. discoideum
development, a process where starvation initiates aggregation and the
formation of multicellular fruiting bodies over a 24-hr period (Kelly et
al., 2018). In this model, development and cellular growth can be
mutually exclusive cell functions, controlled by groups of both
independent and common proteins, providing the opportunity to
assess the effect of CBD on both functions. Cell aggregation and
development led to the formation of mature fruiting bodies in the
absence and presence of CBD (20 μM; Figure 1c), demonstrating that
CBD had no effect on development. Hence, the CBD target is
necessary for cellular growth but is not involved in multicellular
development, suggesting a specific molecular effect in this model
rather than a general toxic effect.
3.2 | Identification of D. discoideum GCVH1 and
H. sapiens GCSH as regulators of CBD cellular function
In order to understand the effect of CBD on D. discoideum growth, we
sought to identify molecular requirements for CBD action by isolating
mutants with reduced CBD sensitivity in a genetic screen of an
insertional mutant library (Figure 2a). A library of mutants was treated
with CBD at a concentration that inhibits cell growth by 80%
(9.5 μM). After 2-week incubation, four CBD-resistant mutants were
isolated and the insertionally inactivated gene potentially controlling
CBD sensitivity was identified using inverse PCR (Keim, Williams, &
Harwood, 2004) or whole-genome sequencing (Figure S1). This
approach identified a CBD-resistant gcvH1− mutant, with an insertion
in exon 1 of gcvH1 (DDB_G0287773) encoding the glycine cleavage
system H protein (GCVH1; Figure 2b). The gcvH1− mutant was
recapitulated in wild-type cells by removal of a central part of the
encoding gene by homologous recombination and the mutant was
confirmed to have lost gcvH1 expression (Figures S2 and S3).
We further assessed if D. discoideum GCVH1 is a likely
homologue of GCSH (UniProt P23434). GCSH and GCVH1 are of
similar size and domain structure and contain a mitochondrial-
targeting peptide sequence at the N-terminus (Figure 2b). Similarly,
both proteins possess a lipoyl-binding domain containing a highly
conserved motif (Figure 2c), including a key lysine residue that binds
the lipoic acid co-factor to facilitate shuttling of the glycine intermedi-
ates within the GCS. This motif is highly conserved throughout the
kingdom of life (Figure 2d; Kikuchi & Hiraga, 1982). This analysis
suggests that the D. discoideum GCVH1 protein is likely to represent a
homologue of the mammalian GSCH, with similar catalytic activity
and function. Since changes in glycine (Boison, 2016; Lynch, 2004;
Xiong et al., 2012) and components of glycine in the one-carbon cycle
such as adenosine have been associated with epilepsy (Boison, 2016;
Kobow et al., 2013), we continued our analysis of this mutant rather
than the other identified mutants (Figure S1).
We then investigated whether the D. discoideum GCVH1
protein localizes to mitochondria, consistent with the localization of
GCSH in mammalian systems using fluorescently tagged gcvH1
(GCVH-RFP) expressed in gcvH1− cells (Figures 3 and S3).
Visualization of the resulting GCVH1-RFP expressing cells showed
localization in small intracellular dots corresponding to mitochondria
seen by phase-contrast microscopy (Figures 3a, S4, S5, and S6). A
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F IGURE 1 Cannabidiol (CBD) is likely to have molecular targets in D. discoideum cell affecting proliferation but not development. (a) The
effect of CBD on D. discoideum cell growth was treated over a 7-day period under a range of indicated concentrations (μM), with CBD blocking
growth at 4 μM (data derived from 6 to 9 independent experiments) and presented as normalized to fold change from control values (untreated,
Day 7). (b) A concentration–response curve of normalized cell density against the Log (concentration) of CBD was used to calculate the IC50 value
with a 95% confidence interval. (c) The effect of CBD on D. discoideum development was analysed using cells plated upon nitrocellulose filters
under starvation conditions where fruiting bodies were formed, shown for a field of fruiting bodies (aerial view) and for a single fruiting body.
Treatment of cells with either 20 μM CBD or vehicle alone did not block development (n = 9)
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similar localization was seen on overexpression of H. sapiens
GCSH-RFP (Figures 3b and S4). To validate this localization, cells
were fixed and probed with antibodies to both RFP and porin, a
mitochondrial protein (Troll et al., 1992). Porin labelling encapsulated
both GCVH1-RFP and GCSH-RFP proteins (Figure 3a,b), consistent
with a mitochondrial matrix localization of both GCS proteins and
the mitochondrial membrane localization of porin. These data,
together with three-dimensional reconstruction of labelling
(Figures 3c, S4, S5, and S6), confirm a localization of the GCVH1
and the H. sapiens orthologue GCSH in mitochondria in
D. discoideum, consistent with a role for these proteins in the GCS.
To confirm a role for gcvH1 in the regulation of CBD
sensitivity, growth resistance to CBD was assessed in the gcvH1−
mutant and following rescue with GCVH1-RFP and GCSH-RFP
proteins. The gcvH1− cell line showed partial resistance to CBD
(Figures 4a and S7) with a growth inhibitory constant (IC50) of
F IGURE 2 Identifying a role for the glycine cleavage system component, GCVH1, in regulating the cellular effect of CBD in D. discoideum. (a)
A genetic screen of an insertional mutant library was carried out to identify mutants unaffected by the inhibitory effects of CBD on growth. (b)
This screen identified GCVH1 as a potential molecular target for CBD, with an insertion in the first of three exons (red triangle), interrupting the
coding region. Both the D. discoideum and the H. sapiens GCVH1 proteins are of similar size and contain highly conserved functional domains,
include a mitochondrial localization sequence/transit peptide and a lipoyl binding domain, containing the ESVKAAS motif for lipoic acid binding.
(c) The lipoic acid binding motif is highly conserved across a broad range of species but absent in the related dihydrolipoyllysine-residue
succinyltransferase (DLST/DLAT) proteins. (d) Such conservation highlights the evolutionary similarity of D. discoideum GCVH1 to orthologues
found in higher organisms
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4.2 μM (95% CI [3.2–5.3 μM]). Expressing either D. discoideum
GCVH1-RFP or H. sapiens GCSH-RFP protein in gcvH1− restored
sensitivity to growth inhibition, with IC50 of 2.2 μM (95% CI
[1.6–2.9 μM]) and 0.82 μM (95% CI [0.67–1.0 μM]) respectively
(Figures 4a, S3, and S7). These data support a role for both
GCVH1 and GCSH in regulating CBD sensitivity, in addition to
confirming a common function of the D. discoideum and the H. sapi-
ens proteins.
To ensure the resistance observed in the gcvH1− mutant was not
from increased xenobiotic degradation or a decreased uptake and
increased removal of CBD, we quantified cellular CBD levels in
mutant and wild-type cells. Here, cells were treated with CBD
(1.89 μM) for 12 hr, and cellular CBD levels were quantified by LC–
MS. No significant difference in CBD levels was found between
wild-type and the gcvH1− cell lines (Figure 4b). This supports the
hypothesis that the effect of CBD is dependent upon a pathway
controlled by the mitochondrial GCS (GCVH1 or GCSH) but not by
CBD metabolic degradation or transport.
3.3 | Monitoring one-carbon cycle amino acids and
folates in D. discoideum following CBD treatment
We then sought to examine the molecular mechanism underlying the
role of GCVH1 in CBD sensitivity, focusing on the function of the
GCS and the interacting FOCM components (Figure 5a). In these
experiments, we first examined the role of GCVH1 in regulating
glycine, methionine, and cysteine levels using GC–MS. We found that
glycine levels were significantly increased in gcvH1− cells compared to
wild-type cells (P < .05), with a moderate decrease in methionine
levels (P < .05) and no change in cysteine levels, supporting a role for
the encoded protein in the GCS (Figure 5b). We then examined the
effect of CBD treatment in both wild-type gcvH1− cells (using
1.89 μM for 12 hr), where CBD gave no change in glycine levels. In
contrast, methionine levels were significantly reduced in wild-type
cells following CBD treatment (P < .05), and this effect was lost in
gcvH1− cells, consistent with a CBD-dependent inhibitory effect on
methionine synthesis that is suppressed in gcvH1− cells (Figure 5b).
F IGURE 4 The CBD-resistant phenotype through loss of GCVH1 is rescued by both D. discoideum GCVH1 and H. sapiens GCSH proteins and
is not caused by reduced CBD uptake or increased removal/degradation. (a) Concentration–response assays of wild-type, gcvH1−, and rescue cell
lines with either the D. discoideum or H. sapiens genes replaced was carried out. Data are mean +/− SEM (*, P < .05 one-way ANOVA, Tukey post
hoc test). (b) Cellular CBD levels were quantified within wild-type D. discoideum and gcvH1− cell lines using LC–MS-IT-TOF following a prolonged
CBD treatment regime (n = 4 or 6 as indicated). Data are mean +/− SEM (P > .05, Student's t-test)
F IGURE 3 The D. discoideum GCVH1 and H. sapiens GCSH proteins localize to mitochondria in D. discoideum. (a) Confocal imaging of
D. discoideum gcvH1− cells expressing D. discoideum GCVH1-RFP, imaged using phase contrast, with RFP fluorescence (red), a porin antibody
(green), and DAPI to visualize DNA (blue), and with a merged fluorescence image on the right. (b) Shows D. discoideum gcvH1− cells expressing
H. sapiens GCSH-RFP, imaged using phase contrast, with RFP fluorescence (red), a porin antibody (green), and DAPI to visualize DNA (blue), and
with a merged fluorescence image on the right. (c) Three-dimensional reconstruction of D. discoideum gcvH1− cells expressing D. discoideum
GCVH1-RFP, using RFP fluorescence (red), filamentous actin imaged using Atto488-phalloidin (green), and DAPI to visualize DNA (blue). Scale
bars correspond to 5 μm
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F IGURE 5 CBD treatment regulates the one-carbon cycle and folate signalling dependent upon the glycine cleavage system in D. discoideum.
(a) A schematic diagram showing how the glycine cleavage system (GCS—green) found within the mitochondria (orange) is linked to the one-
carbon cycle (blue), involving key amino acids—glycine, methionine, and cysteine, with methionine synthase providing the key point of interaction
between the two systems. (b) To analyse changes in these systems, both wild-type and gcvH1− cell lines were treated with CBD (1.89 μM, 24 hr)
or vehicle alone, and their amino acid composition was analysed by GC–MS (n = 6–9). Analysis shows that gcvH1 ablation and CBD treatment
alters the levels of methionine and glycine. (c) Amino acid level changes were supported using NMR analysis (n = 6–9). All data are mean +/− SEM
(*, P < .05, two-way ANOVA, Bonferroni post hoc test). (d) Folate-containing compounds tetrahydrofolate (THF) and 5-methyltetrahydrofolate
(5mTHF) were also assessed following equivalent treatment conditions (n = 3–7) consistent with a reduction in the glycine cleavage system by
loss of GCVH1, and a CBD dependent increase in 50mTHF consistent with a mechanism of CBD through inhibition of methionine production. All
data are mean +/− SEM (*, P < .05, two-way ANOVA, Bonferroni post hoc test)
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Similar notable trend towards reduced cysteine levels (P = .0502) were
observed in wild-type cells following CBD treatment that was again
absent in the gcvH1− mutant (Figure 5b). These data support a role for
CBD in reducing methionine synthase activity, dependent upon GCS
activity. We independently confirmed these changes using an NMR-
based approach with an identical treatment regimen used in the GC–
MS analysis. Again, glycine levels were elevated in the gcvH1− mutant
compared to wild-type cells (P < .05; Figure 5c) but did not change fol-
lowing CBD treatment. Here, CBD treatment again caused a signifi-
cant reduction in wild-type methionine levels (P < .05) with this effect
lost in the gcvH1− mutant (Figure 5c), again consistent with GC–MS
results. Thus, these two distinct approaches highlight a common
effect of CBD in reducing methionine levels and show that the effects
of CBD on these components are reliant upon activity of the GCS.
We continued by analysing the potential effect of CBD treatment
on the relative abundance of folate mediators of one-carbon metabo-
lism, with exploratory analysis of wild-type and gcvH1− cells, using
LC–MS/MS. Comparison of folate profile in wild-type and untreated
gcvH1− cells identified a significant (P < .05) increase in
tetrahydrofolate (THF) levels in mutant, consistent with impaired
activity of the GCS (Leung et al., 2017; Figure 5d). Following CBD
treatment, wild-type cells showed a significant 23% reduction in THF
levels (P < .05), with a concomitant 8% increase in 5-methylTHF
(5mTHF; P < .05; Figure 5d). As with lower methionine abundance,
this effect is consistent with a CBD-dependent block in methionine
synthase activity. In comparison, gcvH1− cells showed a reduced sen-
sitivity to the effect of CBD, with only a 7% increase in THF and a 3%
decrease in 5mTHF following treatment (both P < .05). Hence, differ-
ence in THF levels between gcvH1− cells and wild-type cells (P < .05)
was of greater magnitude following CBD treatment (Figure 5d). These
data implicate a role for CBD in reducing methionine synthase activity
in this model as a potential mechanism underlying diminished THF
production, with ablation of gcvH1− attenuating this effect.
3.4 | Monitoring amino acid regulation in a Dravet
syndrome epilepsy model following CBD treatment
We then investigated potential changes in amino acid signalling in
epilepsy models. First, we employed a heterozygous Scn1a+/−
mouse model lacking one copy of the NaV1.1 protein (Thiele et al.,
2018) that is used as a model for a variety of seizure types from
simple febrile seizures to severe genetic disorders such as Dravet
(Nakayama et al., 2018) and Lennox–Gastaut syndromes (Zhou et
al., 2018). We initially analysed brain amino acid levels in healthy
(wild-type) and Scn1a+/− mice, where a significant increase in
glycine (P < .05) and methionine (P < .05) levels and a decrease in
cysteine (P < .05) levels were found in these epileptic model mice
compared to wild-type controls (Figure 6a). We also examined
potential changes in these amino acids following 6-week CBD
treatment (twice daily subcutaneous injection at 100 mgkg−1). In
CBD-treated Scn1a+/− animals, glycine, methionine, and cysteine
remained deregulated compared to untreated animals (Figure 6a),
consistent with a role of these elevated amino acid levels providing
a trait marker for Dravet syndrome, although methionine levels
significantly increased (P < .05) following CBD treatment above that
of untreated animals. This CBD-dependent increase was
unexpected, as brain levels of methionine are normally tightly
regulated in healthy animals (Gupta et al., 2004; Selmer, Lund,
Brandal, Undlien, & Brodtkorb, 2009). These insights suggest that
F IGURE 6 A Dravet syndrome model and an in vitro seizure model implicate the one-carbon (amino acid) cycle as a potential mechanistic
target of cannabidiol (CBD) treatment in epilepsy. (a) Analysis of one-carbon cycle amino acids (glycine, methionine, and cysteine) in a mouse
Scn1a+/− Dravet model suggests significant dysregulation of these amino acids in brain tissue, with chronic CBD-treatment further modifying
methionine levels. (b) Analysis of rat primary hippocampal neurons, pretreated with CBD (60 min 1.89 μM), or following induction of seizure-like
activity induced with PTZ (with or without CBD treatment), shows no alteration in glycine or cysteine levels but demonstrates elevates
methionine levels upon seizure induction, with this increase attenuated by CBD treatment. Data are shown as mean ± SEM (*, P < .05, one-way
ANOVA, Tukey post hoc test, n ≥ 7)
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in the Dravet model, extended treatment with CBD modulates
levels of methionine, a key component of one-carbon metabolism.
3.5 | Monitoring one-carbon metabolism amino
acids in an in vitro seizure model following CBD
treatment
Since the Dravet model mice showed altered levels of methionine fol-
lowing long-term CBD treatment, we also employed an in vitro seizure
model to investigate potential changes in this amino acid (and glycine
and cysteine) at a cellular level following acute CBD treatment. Here,
primary hippocampal neurons from wild-type rats were matured for
21 days to develop synaptic connections and pretreated with CBD
(1.89 μM for 60 min) followed by the induction of seizure-like activity
by treatment with 5-mM PTZ for 20 min (Chang et al., 2014). PTZ is
known to be a GABAA receptor antagonist and has been used exten-
sively in epilepsy research to induce seizure activity by preventing the
inhibitory response of GABA (Armand, Louvel, Pumain, & Heinemann,
1998). In this acute model, neurons showed a significant increase in
methionine levels following seizure induction (P < .05), consistent with
that observed in the Dravet model brain, while this increase was sig-
nificantly reduced by pretreatment with CBD (P < .05; Figure 6b). No
significant changes in cysteine or glycine levels were found following
seizure-like activity or with CBD treatment in this model (Figure 6b).
These data suggest that induction of seizure-like activity elevates neu-
ronal methionine levels, and acute CBD treatment attenuates this
effect. Thus, both chronic and acute CBD treatment regulate methio-
nine levels, suggesting a novel effect not previously reported and
potentially related to the therapeutic mechanism of CBD.
4 | DISCUSSION
Understanding the therapeutic mechanism(s) of Cannabis-derived
compounds has been a recent priority in research, particularly in the
treatment of epilepsy. Here, we investigated potential mechanisms
underlying the molecular function of CBD using D. discoideum as a
tractable 3Rs (replacement, refinement, or reduction) model organism
that has been used in a range of other pharmacogenetic studies
including those focused on epilepsy (Chang et al., 2012; Kelly et al.,
2018; Warren et al., 2018). Using this model enabled the
identification of a mechanism for CBD dependent upon the
mitochondrial GCS protein, GCVH1, a component of FOCM, where
this role that is conserved with the human orthologue (GCSH). We
demonstrated that GCVH1 localized to mitochondria, consistent with
studies of GCSH in other models (Lamers et al., 2009; Leung et al., 2017).
Loss of GCVH1 significantly elevated glycine levels, increased THF levels,
and reduced 5mTHF levels, all confirming impaired activity of the GCS in
this mutant (Figure 5). Loss of GCVH1 also led to lower methionine levels
(using GC/MS analysis), consistent with impaired GCS activity leading to
decreased conversion of homocysteine to methionine via methionine
synthase (MTR). Thus, loss of GCVH1 gives rise to metabolic outcomes
that resembles those in mouse and human studies (Lamers et al., 2009;
Leung et al., 2017) and highlights an evolutionarily conserved function of
this important metabolic pathway.
We then demonstrated that CBD functions to modulate
methionine levels and folate intermediates in the one-carbon cycle,
dependent upon GCVH1 activity, revealing a novel role for CBD in
inhibition of methionine production. The increased resistance of
gcvH1− mutants to CBD is modest, with a twofold decrease in
sensitivity, suggesting that this mechanism may represent one of
multiple cellular mechanisms commonly found in therapeutic natural
products and drugs (Kobayashi, Endoh, Ohmori, & Akiyama, 2019;
Zhang, Huai, Miao, Qian, & Wang, 2019) but still demonstrates a role
for the GCS in regulating CBD cellular effects. However, in our
studies, CBD treatment did not increase glycine levels, arguing against
a direct inhibitory effect of CBD on the GCS. Excitingly, treatment of
wild-type cells with CBD lowered methionine levels, and this effect
was lost in the gcvH1− mutant, suggesting a mechanism of CBD action
through inhibition of methionine production. Although we were
unable to detect homocysteine in cells, cysteine levels showed a trend
for a CBD-dependent reduction in wild-type cells that was absent in
the gcvH1− mutant, also consistent with a role for CBD in regulating
GCS-dependent one-carbon metabolism. CBD treatment also caused
a decrease in relative abundance of THF and an increase in 5mTHF,
supporting the hypothesis of a role for CBD in suppressing
methionine synthase activity, with this affect attenuated by loss of
GCVH1. These data therefore provide evidence for CBD-dependent
regulation of one-carbon metabolism in D. discoideum, in which
methionine levels are lowered in a GCS-dependent manner, revealing
a new molecular pathway modulated by CBD.
We then sought to translate this research to a relevant epilepsy
model. Employing a mouse Scn1a+/− mutant to investigate a potential
mechanism of CBD provided a logical approach, as this model
reproduces seizure types found in patients with Dravet syndrome
(Marini et al., 2011) and Lennox–Gastaut syndrome (Selmer et al.,
2009). Surprisingly, we demonstrated that brain levels of glycine,
methionine, and cysteine were all significantly altered in the model,
suggesting that neuronal levels of these amino acids may provide trait
markers for epilepsy. Interestingly, epilepsy is a key feature of
non-ketotic hyperglycinemia (also known as glycine encephalopathy),
an autosomal recessive neurometabolic disorder characterized by
elevated levels of glycine in blood and CSF (Swanson et al., 2015)
caused by mutation of components of the GCS (Kure et al., 2006).
These observations provide a potential link between Dravet
syndrome, mitochondrial function and glycine levels, and non-ketotic
hyperglycinemia. Since mitochondrial dysfunction in Dravet syndrome
has been suggested from studies of patient skin fibroblasts (Doccini et
al., 2015), in patients (Panneman et al., 2018), in a zebrafish model
(Kumar et al., 2016), and in epilepsy-related oxidative stress
(Pearson-Smith et al., 2017), our data support and extend these
findings. Thus, this mechanism may now be added to those already
proposed for CBD in epilepsy treatment (Xiong et al., 2012; Kaplan et
al., 2017, Rodriguez-Munoz et al., 2018, Vilela et al., 2017,
Rimmerman et al., 2013).
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In vivo studies can be complicated by chronic treatment causing
long-term cellular and physiological changes in the brain and the
presence of a variety of cell types. To overcome these considerations,
we analysed a role for CBD in regulating glycine, methionine, and
cysteine levels using an acute neuronal seizure model (Chang et al.,
2014). This approach defines acute changes found during seizures,
and in response to drug treatment, where changes in level of these
components would identify a role in seizures. We showed that
seizure-like activity did not alter glycine or cysteine levels in neurons
themselves, however methionine levels were significantly increased,
and this increase was attenuated by CBD treatment. These data are
consistent with an acute role for CBD in reducing methionine
production in seizure activity but do not prove this—since CBD may
simply block seizure activity, and hence a seizure-dependent increase
in methionine. This could be examined in further experiments, with
other anticonvulsants used to block seizure activity and methionine
levels examined, and this represents a limitation in the present study.
However, our results clearly indicate that seizure activity elevates
methionine levels, revealing a new and unexpected effect of seizure
activity. Differing effects of CBD treatment in the Dravet in vivo
model and in primary neurons in vitro may be due to a range of
factors including long-term cellular and physiological changes in brain
following treatment. Whole-brain material also comprises a variety of
cell types, where the GCS is mainly in glia cells not neurons, and these
aspects will need further investigation.
One-carbon metabolism includes a wide range of components
implicated in neuronal excitability, seizure activity, and epilepsy.
Glycine acts as a co-agonist at excitatory NMDA receptors to provide
a key neuronal glutamatergic (excitability) mechanism and through
specific excitatory and inhibitory receptors (Lynch, 2004). The
production of SAM provides a central function in the cycle, acting as
the primary donor of methyl groups within cells for both DNA and
neurotransmitter methylation (Moore et al., 2013). Adenosine has also
been shown to regulate seizure activity (Boison, 2016) and is involved
in DNA methylation to regulate epileptogenesis (Kobow et al., 2013),
although CBD treatment attenuates the reduction in DNA
methylation induced by cell differentiation (Pucci et al., 2013). Finally,
homocysteine is a pro-convulsant and is elevated in patients with
recurrent seizure activity during treatment with antiepileptic drugs
(Baldelli et al., 2010). Thus, one-carbon metabolism provides a wide
variety of potential impacts on seizure activity and epilepsy control,
further emphasized by the current study.
In summary, our data provide new insights to altered
metabolism in epilepsy as a disease state, and potential therapeuti-
cally relevant mechanisms of CBD action. Future research should
thus investigate changes in one-carbon metabolism in epilepsy,
including Dravet syndrome, and other CBD-treatable disorders,
particularly where potential mitochondrial dysfunction may underlie
some pathological symptoms. We further suggest that
pharmacological regulation of methionine levels during seizure
activity may provide a novel therapeutic approach for seizure
control and one-carbon cycle components may provide diagnostic
markers within a clinical setting.
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